Entity

Time filter

Source Type

Hainan, China

Wang H.,Northwest Normal University | Wang R.,Northwest Normal University | Li H.,Huizhou University | Wang Q.,China Pharma | And 2 more authors.
International Journal of Hydrogen Energy | Year: 2011

One of the key objectives in fuel cell technology is to improve activity and reduce Pt loading of the electrocatalysts. In this work, carbon-supported pseudo-core@shell PdCu@Pt nanoparticles (donated as PdCu@Pt/C) with intimate contact of Pt and PdCu are prepared by a galvanic displacement reaction between PdCu/C alloy nanoparticles and PtCl6 2- in aqueous solution. The core@shell nanostructure is confirmed by transmission electron microscopy, X-ray diffraction, X-ray photoelectron spectroscopy and cyclic voltammetry. The PdCu@Pt/C catalysts demonstrate enhanced specific activity to methanol oxidation and oxygen reduction. The present synthesis route is very facile and economical, which may be suitable for large-scale production of catalysts with low-cost and high activity. © 2010 Professor T. Nejat Veziroglu. Published by Elsevier Ltd. All rights reserved. Source


Hombhanje F.W.,Divine Word University | Huang Q.,China Pharma
Pharmaceuticals | Year: 2010

With the rapidly spreading resistance of Plasmodium falciparum to available non-artemisinin antimalarial drugs, new and novel pharmaceuticals are needed. ARCO® is a new generation ACT, one of several artemisinin-based combinations developed in China to counter antimalarial drug resistance. ARCO® is a derivative of two independently developed antimalarials, artemisinin and naphthoquine phosphate, which were combined to form the artemisinin-naphthoquine combination. Both artemisinin and naphthoquine drugs have proven to be efficacious, safe and well tolerated as monotherapies. The artemisinin- naphthoquine combination offers a novel advantage over existing ACTs: it can be administered as a single oral dose (or a 1-day treatment). Several therapeutic studies conducted recently indicate that a single oral dose administration of artemisinin- naphthoquine combination is equally effective and safe as the 3-day treatment with artemether-lumefantrine combination and other existing ACTs. This would make ARCO® the next generation ACT for the treatment of uncomplicated falciparum malaria. © 2010 by the authors; licensee MDPI, Basel, Switzerland. Source


Kang Z.,Binzhou Medical University | Zhu H.,China Pharma | Luan H.,Binzhou Medical University | Han F.,Binzhou Medical University | Jiang W.,Binzhou Medical University
Neuroscience | Year: 2014

Curculigoside A may be a powerful way of protecting the brain against a wide variety of injury. In the present study, we sought to elucidate whether Curculigoside A contributes to induce angiogenesis and its mechanisms. To this end, we examined the role of Curculigoside A on proliferation, invasion, and tube formation in the human brain microvascular endothelial cell line (HBMEC) in vitro. For studying mechanism, the cAMP response element-binding protein (CREB) inhibitor 2-naphthol-AS-E-phosphate (KG-501), early growth response 3 (Egr-3) siRNA, vascular endothelial growth factor (VEGF) antagonist sFlt-1 and VEGF receptor 2 (VEGFR2) blocker SU-1498 were used. Human brain microvascular endothelial cell line (HMBEC) proliferation was tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Scratch adhesion test was used to assess the ability of invasion. A matrigel tube formation assay was performed to test capillary tube formation ability. Vascular cell adhesion molecule 1 (VCAM-1)/Egr-3/CREB/VEGF pathway activation in HMBEC was tested by Western blot analysis. Our data suggested that Curculigoside A induced angiogenesis in vitro by enhancing the proliferation, invasion and tube formation. VEGF expression was increased by Curculigoside A and counteracted by the soluble VEGF receptor 1 (sFlt-1, VEGF antagonist) and KG-501 in HMBEC. Tube formation was enhanced by Curculigoside A and counteracted by VEGF receptor blocker-SU1498, KG-501 and Egr-3 siRNA. It may be suggested that Curculigoside A induces angiogenesis in vitro via a programed VCAM-1/Egr-3/CREB/VEGF signaling axis. © 2014 IBRO. Source


Jiang T.,China Pharma
Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials | Year: 2011

To study the constituents from the root of Liriope platypgylla. Six chemical constituents were isolated from the chloroform fraction and n-BuOH fraction from EtOH extract of Liriope platyphylla. Their structures were elucidated as beta-sitosterol-3-O-beta-D-glucopyranosile(I), palmic acid (II), ruscogenin (III), LP-C(IV), LP-D(V), 25 (S) -ruscogenin 1-O-beta-D-xylopyranoside-3-O-alpha-L-rhamnopyranoside (VI), respectively. All these compounds are isolated from this plant for the first time. Source


Pan P.,Soochow University of China | Shen M.,Soochow University of China | Yu H.,China Pharma | Li Y.,Soochow University of China | And 3 more authors.
Drug Discovery Today | Year: 2013

Rho-associated protein kinases (ROCK1 and ROCK2) belong to the AGC family of serine-threonine kinases, and regulate a wide range of fundamental cell functions. Inhibition of ROCK has been proven to be of potential therapeutic benefit for a variety of diseases. In this review, the structures and therapeutic importance of ROCK are discussed briefly. Then, the recent status of the development of ROCK inhibitors is also summarized. Our review offers a foundation outline from which strategies to design new leads against ROCK can be developed. © 2013 Elsevier Ltd. All rights reserved. Source

Discover hidden collaborations